Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial
- PMID: 31153882
- DOI: 10.1016/S2468-1253(19)30090-1
Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial
Abstract
Background: The survival benefit of early placement of transjugular intrahepatic portosystemic shunts (TIPS) in patients with cirrhosis and acute variceal bleeding is controversial. We aimed to assess whether early TIPS improves survival in patients with advanced cirrhosis and acute variceal bleeding.
Methods: We did an investigator-initiated, open-label, randomised controlled trial at an academic hospital in China. Consecutive patients with advanced cirrhosis (Child-Pugh class B or C) and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy were randomly assigned (2:1) to receive either early TIPS (done within 72 h after initial endoscopy [early TIPS group]) or standard treatment (vasoactive drugs continued to day 5, followed by propranolol plus endoscopic band ligation for the prevention of rebleeding, with TIPS as rescue therapy when needed [control group]). Randomisation was done by web-based randomisation system using a Pocock and Simon's minimisation method with Child-Pugh class (B vs C) and presence or absence of active bleeding as adjustment factors. The primary outcome was transplantation-free survival, analysed in the intention-to-treat population, excluding individuals subsequently found to be ineligible for enrolment. This study is registered with ClinicalTrials.gov, number NCT01370161, and is completed.
Findings: From June 26, 2011, to Sept 30, 2017, 373 patients were screened and 132 patients were randomly assigned to the early TIPS group (n=86) or to the control group (n=46). After exclusion of three individuals subsequently found to be ineligible for enrolment (two patients in the early TIPS group with non-cirrhotic portal hypertension or hepatocellular carcinoma, and one patient in the control group due to non-cirrhotic portal hypertension), 84 patients in the early TIPS group and 45 patients in the control group were included in the intention-to-treat population. 15 (18%) patients in the early TIPS group and 15 (33%) in the control group died; two (2%) patients in the early TIPS group and one (2%) in the control group underwent liver transplantation. Transplantation-free survival was higher in the early TIPS group than in the control group (hazard ratio 0·50, 95% CI 0·25-0·98; p=0·04). Transplantation-free survival at 6 weeks was 99% (95% CI 97-100) in the early TIPS group compared with 84% (75-96; absolute risk difference 15% [95% CI 5-48]; p=0·02) and at 1 year was 86% (79-94) in the early TIPS group versus 73% (62-88) in the control group (absolute risk difference 13% [95% CI 2-28]; p=0·046). There were no significant differences between the two groups in the incidence of hepatic hydrothorax (two [2%] of 84 patients in the early TIPS group vs one [2%] of 45 in the control group; p=0·96), spontaneous bacterial peritonitis (one [1%] vs three [7%]; p=0·12), hepatic encephalopathy (29 [35%] vs 16 [36%]; p=1·00), hepatorenal syndrome (four [5%] vs six [13%]; p=0·10), and hepatocellular carcinoma (four [5%] vs one [2%]; p=0·68). There was no significant difference in the number of patients who experienced other serious adverse events (ten [12%] vs 11 [24%]; p=0·07) or non-serious adverse events (21 [25%] vs 19 [42%]; p=0·05) between groups.
Interpretation: Early TIPS with covered stents improved transplantation-free survival in selected patients with advanced cirrhosis and acute variceal bleeding and should therefore be preferred to the current standard of care.
Funding: National Natural Science Foundation of China, National Key Technology R&D Program, Optimized Overall Project of Shaanxi Province, Boost Program of Xijing Hospital.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
-
Pre-emptive TIPS in high-risk patients with cirrhosis and variceal bleeding: is it finally time for a conclusion?Lancet Gastroenterol Hepatol. 2019 Aug;4(8):572-573. doi: 10.1016/S2468-1253(19)30172-4. Epub 2019 May 29. Lancet Gastroenterol Hepatol. 2019. PMID: 31153883 No abstract available.
Similar articles
-
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial.Lancet Gastroenterol Hepatol. 2022 Aug;7(8):736-746. doi: 10.1016/S2468-1253(22)00087-5. Epub 2022 May 17. Lancet Gastroenterol Hepatol. 2022. PMID: 35588750 Clinical Trial.
-
Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.Gut. 2018 Dec;67(12):2156-2168. doi: 10.1136/gutjnl-2017-314634. Epub 2017 Sep 28. Gut. 2018. PMID: 28970291 Clinical Trial.
-
Early use of TIPS in patients with cirrhosis and variceal bleeding.N Engl J Med. 2010 Jun 24;362(25):2370-9. doi: 10.1056/NEJMoa0910102. N Engl J Med. 2010. PMID: 20573925 Clinical Trial.
-
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD000553. doi: 10.1002/14651858.CD000553.pub3. Cochrane Database Syst Rev. 2020. PMID: 33089892 Free PMC article.
-
Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis.Cochrane Database Syst Rev. 2018 Oct 31;10(10):CD001023. doi: 10.1002/14651858.CD001023.pub3. Cochrane Database Syst Rev. 2018. PMID: 30378107 Free PMC article.
Cited by
-
TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience.Cancer Imaging. 2022 Feb 19;22(1):13. doi: 10.1186/s40644-022-00451-9. Cancer Imaging. 2022. PMID: 35183265 Free PMC article.
-
Clinical effect of single covered stent and double covered stent on TIPS in the treatment of hemorrhage due to rupture of esophageal and gastric varices in cirrhosis and its influence on immune function.Exp Ther Med. 2019 Dec;18(6):4259-4264. doi: 10.3892/etm.2019.8106. Epub 2019 Oct 15. Exp Ther Med. 2019. PMID: 31772628 Free PMC article.
-
An Update on the Management of Esophageal Variceal Hemorrhage.Clin Liver Dis (Hoboken). 2021 Oct 27;18(4):179-183. doi: 10.1002/cld.1108. eCollection 2021 Oct. Clin Liver Dis (Hoboken). 2021. PMID: 34745574 Free PMC article. Review.
-
Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.Semin Intervent Radiol. 2020 Mar;37(1):3-13. doi: 10.1055/s-0039-3402015. Epub 2020 Mar 4. Semin Intervent Radiol. 2020. PMID: 32139965 Free PMC article. Review.
-
The time window for pre-emptive transjugular intrahepatic portosystemic shunt could be extended to 5 days.Heliyon. 2024 Feb 3;10(3):e25824. doi: 10.1016/j.heliyon.2024.e25824. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38863871 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical